US 12,419,966 B2
In vivo radical-mediated polymerization for targeted delivery of trophic factors
Christopher Lowe, Piscataway, NJ (US); David I. Shreiber, Whitehouse Station, NJ (US); Emily DiMartini, Brick Township, NJ (US); and Adam Gormley, New Brunswick, NJ (US)
Assigned to RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY, New Brunswick, NJ (US)
Filed by Christopher Lowe, Piscataway, NJ (US); David I. Shreiber, Whitehouse Station, NJ (US); Emily DiMartini, Brick Township, NJ (US); and Adam Gormley, New Brunswick, NJ (US)
Filed on Aug. 10, 2021, as Appl. No. 17/398,606.
Application 17/398,606 is a continuation in part of application No. 17/333,067, filed on May 28, 2021, abandoned.
Application 17/333,067 is a continuation of application No. 16/009,033, filed on Jun. 14, 2018, granted, now 11,020,491, issued on Jun. 1, 2021.
Claims priority of provisional application 62/519,465, filed on Jun. 14, 2017.
Prior Publication US 2021/0369864 A1, Dec. 2, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 47/10 (2017.01); A61K 47/32 (2006.01); A61K 47/34 (2017.01); A61K 47/69 (2017.01); C08L 33/06 (2006.01); C08L 33/20 (2006.01); C08L 33/26 (2006.01)
CPC A61K 47/6935 (2017.08) [A61K 47/10 (2013.01); A61K 47/34 (2013.01); C08L 33/06 (2013.01); A61K 47/32 (2013.01); C08L 33/20 (2013.01); C08L 33/26 (2013.01); C08L 2203/02 (2013.01)] 19 Claims
OG exemplary drawing
 
1. A kit for diagnosing or treating a disease or an injury characterized by elevated production of free radicals, comprising:
a first conjugate comprising a first linear or multi-arm polymer covalently linked to one or more optionally substituted reactive alkene addition-reaction functional groups, wherein the reactive alkene functional groups react intermolecularly to form a cross-linked polymer network after being exposed in vivo to an elevated level of free radicals associated with the disease or injury,
wherein the polymer further comprises:
a first cycloaddition functional group;
and
optionally a first cleavable linkage;
a second conjugate comprising a second linear or multi-arm polymer covalently linked to a therapeutic or a diagnostic agent and a second cycloaddition functional group complementary to the first cycloaddition functional group for cycloaddition reaction to occur, optionally wherein the second polymer comprises a second cleavable linkage.